MAPT and Alzheimer disease: The lead candidate, DDL-357, that possessed good drug-like characteristics, was found to increase sCLU in brain in the ApoE4TR-5XFAD murine model of AD, and both decrease phospho-tau (p-tau) and improve memory in the 3xTg-AD murine model of AD.